Difference of in vivo and in vitro antimineralocorticoid potency of progesterone

Endocrine Research

Volumn 28, Issue 4, 2002, Pages 465-470

  Quinkler, M ^a,b   Diederich, S ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PROGESTERONE;

ADDISON DISEASE; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; RECEPTOR AFFINITY; RETICULOCYTE LYSATE; SODIUM URINE LEVEL; THIRD TRIMESTER PREGNANCY;

ADDISON DISEASE; ALDOSTERONE; ANIMALS; BINDING, COMPETITIVE; CELL LINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MINERALOCORTICOIDS; POTASSIUM; PROGESTERONE; RABBITS; RECEPTORS, MINERALOCORTICOID; SODIUM;

EID: 0036941102     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-120016824     Document Type: Conference Paper

References (9)

1. Landau, R.L.; Bergenstal, D.M.; Lugibihl, K.; Kascht, M.E. The metabolic effects of progesterone in man. J. Clin. Endocrinol. Metab. 1955, 15, 1194-1215.
2. Landau, R.L.; Lugibihl K. Inhibition of the sodium-retaining influence of aldosterone by progesterone. J. Clin. Endocrinol. Metab. 1958, 18, 1237-1245.
3. Oparil, S.; Ehrlich, E.N.; Lindheimer, M.D. Effect of progesterone on renal sodium handling in man: Relation to aldosterone excretion and plasma renin activity. Clin. Sci. Mol. Med. 1975, 49 (2), 139-147.
4. Rupprecht, R.; Reul, J.M.; van Steensel, B.; Spengler, D.; Soder, M.; Berning, B.; Holsboer, F.; Damm, K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur. J. Pharmacol. 1993, 247 (2), 145-154.
5. Myles, K.; Funder, J.W. Progesterone binding to mineralocorticoid receptors: In vitro and in vivo studies. Am. J. Physiol. Endocrin. Metab. 1996, 270, E601-E607.
6. Souque, A.; Fagart, J.; Couette, B.; Davioud, E.; Sobrio, F.; Marquet, A.; Rafestin-Oblin, M.E. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology 1995, 136 (12), 5651-5658.
7. Quinkler, M.; Johanssen, S.; Grossmann, C.; Bähr, V.; Müller, M.; Oelkers, W.; Diederich, S. Progesterone metabolism in the human kidney and inhibition of 11β-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. J. Clin. Endocr. Metabol. 1999, 84 (11), 4165-4171.
8. Quinkler, M.; Johanssen, S.; Bumke-Vogt, C.; Oelkers, W.; Bähr, V.; Diederich, S. Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney. Mol. Cell. Endocrin. 2001, 171 (1-2), 21-24.
9. Winkel, C.A.; Simpson, E.R.; Milewich, L.; MacDonald, P.C. Deoxycorticosterone biosynthesis in human kidney: Potential for formation of a potent mineralocorticosteroid in its site of action. Proc. Natl. Acad. Sci. USA 1980, 77 (12), 7069-7073.